{"abstract": "The higher offer quickly put an end to Endo\u2019s rival bid, but the added cost, along with the debt Valeant already holds, may hurt the company.", "web_url": "https://www.nytimes.com/2015/03/17/business/dealbook/valeants-sweetened-bid-for-salix-may-have-delivered-2-knockouts.html", "snippet": "The higher offer quickly put an end to Endo\u2019s rival bid, but the added cost, along with the debt Valeant already holds, may hurt the company.", "lead_paragraph": "The sweetened $11 billion bid by Valeant Pharmaceuticals for Salix Pharmaceuticals may have scored two knockouts. By coming up with an extra 9 percent over its previous offer, the acquisitive drug maker, now backed by the hedge fund executive William A. Ackman, quickly put an end to a rival bid from Endo International. But the extra cash required, and the debt already on its balance sheet, leave Valeant\u2019s business model looking wobbly.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-jumbo.jpg", "height": 682, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-superJumbo.jpg", "height": 1364, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/03/17/business/dbpix-valeantsign/dbpix-valeantsign-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Valeant\u2019s Sweetened Bid for Salix May Have Delivered 2 Knockouts", "kicker": "Breakingviews", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Salix Pharmaceuticals Ltd", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Endo International PLC", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Merck & Company Inc", "rank": 6, "major": "N"}, {"name": "persons", "value": "Ackman, William A", "rank": 7, "major": "N"}], "pub_date": "2015-03-16T21:45:43+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Robert Cyran", "person": [{"firstname": "Robert", "middlename": null, "lastname": "Cyran", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/38f246e6-9e8f-599a-8c48-69100ddea562", "word_count": 387, "uri": "nyt://article/38f246e6-9e8f-599a-8c48-69100ddea562"}